Ochsner Cardiologist Receives International Impact Award
NEW ORLEANS – Hector O. Ventura, MD, FACC, FACP – section head, cardiomyopathy and heart transplantation, John Ochsner Heart and Vascular Institute (JOHVI) – has been recognized by the American Heart Association / American Stroke Association (AHA/ASA) with the 2019 Ron Haddock AHA/ASA International Impact Award. Ochsner Health System made the announcement in a press release.
Awarded annually, this honor recognizes an individual or group of individuals for outstanding contributions which have advanced AHA/ASA international goals. Recipients are recognized as a leader or major contributor in an activity, enterprise or program of the AHA at the international level. Dr. Ventura was recognized with this honor during the annual AHA/ASA awards luncheon this June in Plano, Texas.
Ventura holds more than 35 years’ experience in healthcare and currently serves on the AHA International Committee. He has volunteered extensively to leading international initiatives focused on distance learning and equity in care, including the Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Disease Outcomes (CREDO). Additionally, he is a past AHA/ACC Vice President, United States Representative, to the InterAmerican Society of Cardiology, Executive Council.
Ventura is board certified in cardiology and holds a medical degree from the National University School of Medicine in Buenos Aires, Argentina. Highlights from his extensive medical training include a residency at the Central Military Hospital in Buenos Aires; an internship and residency at Ochsner where he also completed fellowships in arterial hypertension and cardiovascular diseases; and a fellowship in heart failure and transplantation at Loyola University in Chicago, Illinois. Dr. Ventura has served in his current position at Ochsner since 2000.
JOHVI has been a regional and national leader in cardiology and cardiac surgery for decades. JOHVI is home to more than 50 cardiologists and surgeons who work closely with each patient to develop a customized healthcare plan that is both targeted and effective. Ochsner also participates in more than 100 clinical trials for the goal of advancing knowledge of the mechanisms, treatments and diagnoses of cardiovascular disease.